Atea Pharmaceuticals, Inc. (AVIR) stock

Add to watchlist

Add holding +

NASDAQ: AVIR Nasdaq Biotechnology Next results ~November 11, 2026

Atea Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Insiders1 buying, 0 selling1 purchase and 0 sales by directors and officers, last 12 monthsInsider trades
Funds63 adding, 58 cuttingOf 24 active managers that changed their stake, 13 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 26% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

High operating margin. 39.4% of revenue is left as operating profit.
Shrinking share count. Diluted shares fell 6.4% in a year, so each share owns more of the business.
Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

Volatile shares. Over the past year the shares showed annualised volatility of 51% and a beta of 0.8 against the S&P 500.

Latest results: FY2021 Q4

Filed February 28, 2023

Earnings per share: -$0.41 against an average estimate of -$0.56: beat by 26.1%
Revenue: $192m
Share reaction: +0.4% in the first session after the results on August 12, 2026, against +0.9% for the S&P 500
Next report: November 11, 2026; average EPS estimate -$0.51

Atea Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

1 day-0.2%
1 week-1.4%
1 month-20.1%
This year+14.8%
1 year+26.2%
5 years-65.8%
S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted): $-2.09

Growth

Share count change: −6.4%

Earnings

Last results: August 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

August 12, 2026Results

Atea Pharmaceuticals, Inc. reported results

SEC 8-KRead source ↗

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Atea Pharmaceuticals, Inc. valuation models and calculator

No model value for Atea Pharmaceuticals, Inc. at the moment. Current status: data-quality checks not passed. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 11, 2026. Analysts expect revenue of $0 and EPS of −$0.51 (range −$0.59 to −$0.42) for the quarter.

Analysts' consensus

Atea Pharmaceuticals, Inc.: consensus estimates
Fiscal year	EPS	Growth	Revenue	Growth
Current	−$1.99	−2%	—	0%
Next	−$1.48	+25%	$30m	0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +20.3% on 90 days ago. In the last 30 days, 0 analysts raised Atea Pharmaceuticals, Inc.'s forecast and 2 cut it.

Consensus EPS forecast Atea Pharmaceuticals, Inc., last 90 days

Average of analysts' published estimates (third-party data).

View chart data

Period	Current fiscal year	Next fiscal year
90 days ago	−$1.65	−$1.38
60 days ago	−$1.93	−$1.39
30 days ago	−$1.93	−$1.39
7 days ago	−$1.93	−$1.39
Now	−$1.99	−$1.48

Earnings against estimates

Atea Pharmaceuticals, Inc.: reported EPS against the consensus estimate
Quarter to	Estimate	Actual	Surprise
Jun 2026	−$0.56	−$0.41	+26.1%
Dec 2025	−$0.48	−$0.57	−17.5%
Sept 2025	−$0.41	−$0.53	−27.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

3 analysts, Oct 2026

Buy267%

Hold133%

Sell00%

Monthly trend

Oct 2026213
Sep 2026213

Counts of recommendations published by analysts covering Atea Pharmaceuticals, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest: 4.9%
Days to cover: 10.36
Short interest, 1 month: −60%
Held by institutions: 79%
Held by insiders: 13.4%
Employees: 55

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Atea Pharmaceuticals, Inc.: yearly return, monthly win rate and worst fall against the S&P 500
Calendar year	2021	2022	2023	2024	2025	2026 to date
Return
AVIR	−79%	−46%	−37%	+10%	+7%	+15%
Industry peers (median)	−35%	−57%	−17%	−29%	−5%	−27%
S&P 500	+29%	−18%	+26%	+25%	+18%	+11%
Months that ended higher
AVIR	58%	42%	25%	42%	42%	55%
S&P 500	75%	42%	67%	75%	75%	46%
Largest fall from a high during the year
AVIR	−91%	−53%	−45%	−36%	−28%	−34%
S&P 500	−5%	−25%	−10%	−8%	−19%	−9%

Worst fall since October 30, 2020: 97% from February 8, 2021 to May 14, 2025. Getting back needed a 3368% gain, and the shares have not yet recovered.

Price behaviour

52-week range: $2.96 – $6.15
From 52-week high: −33.3%
vs 50-day average: −18.3%
vs 200-day average: −16.9%
Volatility (1 year): 51%
Beta vs S&P 500: 0.83

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day: 4 up, 8 down
After a week: 5 up, 7 down
After a month: 5 up, 7 down

Atea Pharmaceuticals, Inc.: share-price change after each results release
Results released	Next day	S&P 500 next day	5 days	21 days
August 12, 2026	+0.4%	+0.9%	+10.7%	+5.1%
May 12, 2026	−15.5%	+0.4%	−23.3%	−19.4%
March 5, 2026	+18.3%	−1.9%	+22.5%	+17.9%
January 8, 2026	−0.9%	+0.7%	−1.1%	+19.0%
November 12, 2025	−9.5%	−1.6%	−6.8%	−6.8%
August 7, 2025	−3.2%	+0.7%	0.0%	−6.9%
May 12, 2025	−3.3%	+4.0%	+3.3%	+16.7%
April 17, 2025	−4.7%	−2.2%	−3.7%	−6.3%
March 6, 2025	−0.7%	−1.2%	+1.7%	−7.3%
January 14, 2025	+3.7%	+2.0%	−2.5%	−2.8%
November 7, 2024	−2.2%	+1.2%	−7.5%	−15.6%
August 7, 2024	+6.4%	+1.6%	+9.4%	+9.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Atea Pharmaceuticals, Inc.: annual financial statements
Fiscal year	2020 Dec 2020	2021 Dec 2021
Income
Revenue	49	351
EBITDA	−11	138
Operating income	−11	138
Net income	−11	121
Diluted EPS	−$0.13	$1.37
Growth (year on year)
Revenue	—	+622.5%
Margins
EBITDA margin	−22.6%	39.4%
Operating margin	−22.7%	39.4%
Net margin	−22.5%	34.5%
Free-cash-flow margin	610.1%	−24.8%
Cash flow
Cash from operations	297	−87
Capital spending	0	0
Free cash flow	297	−87
Stock-based pay	7	40
Free cash flow after stock pay	289	−127
Balance sheet
Cash	850	764
Total debt	0	0
Net debt (negative = net cash)	−850	−764
Diluted shares	86m	88m

US$ millions unless shown otherwise. Fiscal quarters; growth is against the same quarter a year earlier.

Atea Pharmaceuticals, Inc.: quarterly financial statements
Quarter	2021 Q1 Mar 2021	2021 Q2 Jun 2021	2021 Q3 Sept 2021	2021 Q4 Dec 2021
Income
Revenue	66	60	33	192
EBITDA	31	9	−22	121
Operating income	31	9	−22	121
Net income	31	2	−28	117
Diluted EPS	$0.34	$0.02	−$0.34	$1.32
Margins
EBITDA margin	46.5%	14.4%	−67.5%	63.1%
Operating margin	46.5%	14.4%	−67.5%	63.1%
Net margin	46.5%	2.5%	−85.9%	60.9%
Cash flow
Cash from operations	−17	−17	23	−75
Stock-based pay	7	10	11	11

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Dividends, buybacks and capital spending

Diluted share count: −6.4%; year over year

Competitors: side by side with peers

Closest by revenue in biotechnology

Growth, margins and cash generation against peers
Last 12 months unless stated	AVIR	PHAR	IOVA	SVA	ARVN	MNKD	Median
Revenue, last 12 months	$351m	$376m	$325m	$386m	$317m	$394m	$58m
Revenue growth, last 12 months	—	26.6%	34.5%	6.8%	−15.0%	30.5%	12.6%
Revenue growth, 3-year average	—	—	—	66.1%	26.1%	35.5%	13.7%
Revenue growth, latest quarter	—	—	65.7%	—	>999%	42.9%	10.2%
Gross margin	—	87.9%	48.4%	67.9%	—	89.8%	82.9%
Operating margin	39.4%	6.9%	−92.7%	−127.0%	−5.7%	2.3%	−187.2%
Operating margin, 3-year average	—	—	−554.7%	−3.3%	−145.1%	14.4%	−363.5%
Net margin	34.5%	0.8%	−89.1%	−15.5%	2.9%	−11.1%	−163.5%
Cash from operations / revenue	−24.8%	14.5%	−81.3%	−132.7%	−65.4%	−2.0%	−162.3%
Free-cash-flow margin	—	14.3%	−91.2%	−145.4%	−65.9%	−4.6%	−162.4%
Free-cash-flow margin, 3-year average	—	—	−482.4%	−14.0%	−135.2%	4.1%	−310.0%
Stock pay / revenue	11.3%	3.7%	14.4%	0.0%	11.6%	7.1%	19.2%
Change in share count	−6.4%	−4.9%	29.6%	0.0%	−7.6%	6.1%	8.1%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling

Reported value: $276M
Institutions reporting: 124
Shares held vs prior quarter: ▼ 1.1%
Positions opened / closed: 17 / 20

63 bought 58 sold

Top buyers and sellers, Q2 2026: 63 institutions bought and 58 sold ; the biggest buyer was Acadian Asset Management LLC (+452K shares) and the biggest seller Jane Street Group, LLC (−418K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager	Value	Shares	Share of 13F value	Shares QoQ
FMR LLC	$55.8M	12.0M	20.2%	▲ 0.4%
Blackrock, Inc.	$40.5M	8.7M	14.7%	▲ 3.4%
Bml Capital Management, LLC	$32.3M	7.0M	11.7%	▼ 1.5%
Tang Capital Management LLC	$22.4M	4.8M	8.1%	0.0%
Vanguard Capital Management LLC	$13.8M	3.0M	5.0%	▼ 8.7%
Bain Capital Life Sciences Investors, LLC	$9.7M	2.1M	3.5%	▼ 12.1%
Acadian Asset Management LLC	$9.5M	2.0M	3.4%	▲ 28.6%
Geode Capital Management, LLC	$9.1M	2.0M	3.3%	▲ 12.1%
State Street Corp	$7.7M	1.7M	2.8%	▼ 2.5%
Two Sigma Investments, LP	$7M	1.5M	2.5%	▼ 19.2%
Dimensional Fund Advisors LP	$6M	1.3M	2.2%	▲ 3.5%
Renaissance Technologies LLC	$5.3M	1.1M	1.9%	▼ 3.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Atea Pharmaceuticals, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart

Insider purchases History → $25,437 1 trade by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders

Net ▲ $25,437 net buying

Recent insider open-market transactions
Insider	Date	Trade	Shares	Price	Value
Murphy Polly A. Director	May 18, 2026	Buy	6,100	$4.17	$25,437

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

August 12, 2026
May 12, 2026
March 5, 2026
January 8, 2026
November 12, 2025
August 7, 2025

Recent SEC filings

10-Q Quarterly report August 12, 2026
8-K Current report August 12, 2026
8-K Current report June 22, 2026
10-Q Quarterly report May 12, 2026
8-K Current report May 12, 2026
DEF 14A Proxy statement April 27, 2026
10-K Annual report March 5, 2026
8-K Current report March 5, 2026

Data status

When each part of this page on Atea Pharmaceuticals, Inc. was last updated.

Data	Last updated	Source
Share price	November 2, 2026	Exchange closing prices
Financial statements	February 28, 2023	SEC 10-K and 10-Q filings
News and updates	October 31, 2026, 7:55pm ET	Company releases and SEC 8-K filings
Analyst estimates	October 31, 2026, 9:14am ET	Aggregated analyst estimates
Valuation and scores	November 3, 2026, 9:10am ET	Our models, from the filed figures

How we build and check these figures: methodology and data sources.

Atea Pharmaceuticals, Inc. in brief

What does Atea Pharmaceuticals, Inc. do?: Atea Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Atea Pharmaceuticals, Inc.'s stock ticker?: Atea Pharmaceuticals, Inc. trades under the ticker AVIR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Atea Pharmaceuticals, Inc.'s largest institutional shareholders?: By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Blackrock, Inc. and Bml Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Atea Pharmaceuticals, Inc.'s market cap?: On December 31, 2021, Atea Pharmaceuticals, Inc.'s market capitalisation was about $789M, with a price-to-earnings ratio of 6.5 and net debt of -$764M. Market figures come from third-party market data and may be delayed.
Who are Atea Pharmaceuticals, Inc.'s competitors?: In our Biotechnology peer group, the companies closest to Atea Pharmaceuticals, Inc. are Pharming Group N.V., Iovance Biotherapeutics, Inc., Sinovac Biotech LTD, Arvinas, Inc. and Mannkind Corp. The side-by-side comparison below sets their revenue, margins and growth against Atea Pharmaceuticals, Inc.'s.
Are insiders buying or selling Atea Pharmaceuticals, Inc. stock?: Over the last 12 months, Atea Pharmaceuticals, Inc.'s directors and officers reported 1 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Atea Pharmaceuticals, Inc.'s next earnings date?: Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Atea Pharmaceuticals, Inc. announces its own schedule.